 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 2109 | 回復(fù): 8 | ||||
| 當(dāng)前只顯示滿足指定條件的回帖，點(diǎn)擊這里查看本話題的所有回帖 | ||||
mollyzhang版主
|
[交流]
FDA批準(zhǔn)強(qiáng)生Canagliflozin用于2型糖尿病 已有7人參與
|
|||
|
2013年1月11日訊 /生物谷BIOON/ --強(qiáng)生旗下的楊森制藥公司10日宣布，其糖尿病藥物canagliflozin（商品名 INVOKANA™）獲得FDA專家委員會10：5投票推薦批準(zhǔn)，用于治療成人2型糖尿病。 Canagliflozin是一種SGLT2抑制劑藥物，能通過將葡萄糖分解后通過腎臟排出體外的方式來降低血糖，具有廣闊前景。（生物谷Bioon.com） 20130111101812190.png FDA Advisory Committee Recommends Approval of Canagliflozin for Treatment of Adults with Type 2 Diabetes RARITAN, NJ, January 10, 2013 – Janssen Research & Development, LLC (Janssen) announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10 – 5 to recommend approval for canagliflozin, proposed trade name INVOKANA™, to treat type 2 diabetes in adult patients based on the efficacy and safety results from its comprehensive clinical development program. Canagliflozin is an investigational, oral, once-daily medication for the treatment of adult patients with type 2 diabetes. If approved by the FDA later this year, it would be the first in this new class of diabetes therapies available in the U.S. The kidneys of people with type 2 diabetes reabsorb greater amounts of glucose back into the body compared to people who do not have diabetes, which may contribute to elevated glucose levels. Canagliflozin, a selective sodium glucose co-transporter 2 (SGLT2) inhibitor, blocks the reabsorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose levels in people with diabetes who have elevated blood glucose levels. “We are pleased with the positive recommendation from the committee and look forward to working with the FDA to bring this important new therapy to patients in the U.S. to help them manage their type 2 diabetes,” said Peter Stein, M.D., Head, Metabolism Development, Diabetes Disease Area Leader, Janssen. "Today’s outcome represents an important step toward achieving that goal." Data presented at today’s advisory committee meeting included results from the comprehensive global Phase 3 clinical program, which enrolled 10,285 patients in nine studies; it is the largest late-stage development program for an investigational pharmacologic product for the treatment of type 2 diabetes submitted to health authorities to date. Canagliflozin was evaluated at 100 mg and 300 mg once-daily doses in placebo- and active comparator-controlled studies, as well as three large studies in special populations: older patients, patients with moderate renal impairment, and patients who had or were at risk for cardiovascular disease. Results showed that in addition to the improvements in glycemic control, both doses of canagliflozin were associated with weight loss and reductions in blood pressure across clinical studies. Canagliflozin was generally well tolerated. It has specific safety and tolerability issues that were well characterized in this development program (such as the genital mycotic infections, urinary tract infections) and can be well managed by the physician and by the patient for some of these issues. Janssen presented data from Phase 3 studies at the American Diabetes Association (ADA) in Philadelphia in June, at the European Association for the Study of Diabetes (EASD) in Berlin in October, and at the World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy) in Barcelona in November. The FDA will consider the advisory committee recommendation in its review of the New Drug Application (NDA) for canagliflozin that was submitted by Janssen on May 31, 2012, though the FDA is not bound to follow it. Janssen and its affiliates have rights to canagliflozin through a license agreement with Mitsubishi Tanabe Pharma Corporation. Janssen Pharmaceuticals, Inc. and its affiliates have marketing rights in North America, South America, Europe, the Middle East, Africa, Australia, New Zealand, and parts of Asia. [ Last edited by mollyzhang on 2013-1-12 at 12:52 ] |
回復(fù)此樓» 收錄本帖的淘帖專輯推薦
 新藥研發(fā) |
» 猜你喜歡
CSC改派-博士生交流訪學(xué)
已經(jīng)有19人回復(fù)
-
中山大學(xué)-第七醫(yī)院-招科研助理1名（基因設(shè)計(jì)和克隆、RNA合成）
已經(jīng)有0人回復(fù)
-
藥理學(xué)論文潤色/翻譯怎么收費(fèi)?
已經(jīng)有114人回復(fù)
-
中山大學(xué)-第七醫(yī)院-招科研助理1名（基因設(shè)計(jì)和克隆、RNA合成）
已經(jīng)有1人回復(fù)
-
巴黎薩克雷大學(xué)與國家留學(xué)基金委合作博士研究生項(xiàng)目-脂質(zhì)納米藥物/生物材料/多酚遞送
已經(jīng)有10人回復(fù)
-
錦州醫(yī)科大學(xué)藥用生物材料（專業(yè)代碼1007Z1）招收調(diào)劑考生
已經(jīng)有0人回復(fù)
-
錦州醫(yī)科大學(xué)藥用生物材料（專業(yè)代碼1007Z1）招收調(diào)劑考生
已經(jīng)有2人回復(fù)
-
26申博自薦
已經(jīng)有12人回復(fù)
-
SUES&NERCN課題組接受碩士生調(diào)劑 (學(xué)碩1名+專碩1名)
已經(jīng)有0人回復(fù)
-
SUES&NERCN課題組接受碩士生調(diào)劑 (學(xué)碩1名+專碩1名)
已經(jīng)有0人回復(fù)
xjxiaojing
超級版主
- 應(yīng)助: 0 (幼兒園)
- 金幣: 667.5
- 帖子: 64
- 在線: 54.6小時(shí)
- 蟲號: 699551
- 注冊: 2009-02-11
- 性別: MM
- 專業(yè): 合成藥物化學(xué)
8樓2013-01-14 16:13:10
achunok
主管區(qū)長
從十品
- 應(yīng)助: 20 (小學(xué)生)
- 金幣: 14267.6
- 散金: 710
- 紅花: 18
- 帖子: 2251
- 在線: 222小時(shí)
- 蟲號: 233888
- 注冊: 2006-03-30
- 性別: GG
- 專業(yè): 有機(jī)合成
3樓2013-01-12 15:24:03
h_chen
管理員
- 應(yīng)助: 33 (小學(xué)生)
- 金幣: 6522.1
- 散金: 675
- 紅花: 10
- 帖子: 1898
- 在線: 182小時(shí)
- 蟲號: 1088109
- 注冊: 2010-09-03
- 性別: GG
- 專業(yè): 天然有機(jī)化學(xué)
4樓2013-01-12 16:52:13
癡夢瀟湘
主管區(qū)長
- 應(yīng)助: 16 (小學(xué)生)
- 金幣: 3897.3
- 散金: 2200
- 紅花: 107
- 沙發(fā): 8
- 帖子: 2857
- 在線: 1192.5小時(shí)
- 蟲號: 1120792
- 注冊: 2010-10-12
- 性別: GG
- 專業(yè): 藥物化學(xué)
5樓2013-01-12 16:58:18
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 266分求材料化工冶金礦業(yè)等專業(yè)的調(diào)劑 +5 | 哇呼哼呼哼 2026-03-26 | 5/250 |
|
|---|---|---|---|---|
|
|
[考研] 085601一志愿中山大學(xué)深圳材料工程330求調(diào)劑 +6 | pipiver 2026-03-30 | 6/300 |
|
|
[考研] 英一數(shù)一408，總分284，二戰(zhàn)真誠求調(diào)劑 +10 | 12.27 2026-03-30 | 12/600 |
|
|
|
[考研] 296求調(diào)劑 +3 | 汪��？！ 2026-03-31 | 6/300 |
|
|
|
[考研] 271求調(diào)劑 +11 | 勒布朗@ 2026-03-31 | 13/650 |
|
|
|
[考研] 311（085601）求調(diào)劑 +12 | liziyeyeye 2026-03-28 | 13/650 |
|
|
|
[考研] 085601英二數(shù)二求調(diào)劑 總分325 +4 | 余航航 2026-03-31 | 4/200 |
|
|
|
[考研] 材料求調(diào)劑 一志愿哈工大總分298分，前三科223分 +11 | dongfang59 2026-03-27 | 11/550 |
|
|
|
[考研] 085600 295分求調(diào)劑 +13 | W55j 2026-03-30 | 15/750 |
|
|
|
[考研] 083000學(xué)碩274求調(diào)劑 +12 | Li李魚 2026-03-26 | 12/600 |
|
|
|
[考研] 22408 359分調(diào)劑 +4 | Qshers 2026-03-27 | 8/400 |
|
|
|
[考研] 一志愿中海洋320化學(xué)工程與技術(shù)學(xué)碩求調(diào)劑 +8 | 披星河 2026-03-30 | 8/400 |
|
|
|
[考研] 317分 一志愿南理工材料工程 本科湖工大 求調(diào)劑 +12 | 芋泥小鈴鐺 2026-03-28 | 12/600 |
|
|
|
[考研] 295求調(diào)劑 +5 | wei-5 2026-03-26 | 5/250 |
|
|
|
[考研] 本科新能源科學(xué)與工程，一志愿華理能動285求調(diào)劑 +3 | AZMK 2026-03-27 | 5/250 |
|
|
|
[考研] 求調(diào)劑 +6 | 蘆lty 2026-03-25 | 7/350 |
|
|
|
[考研] 藥學(xué)105500求調(diào)劑 +3 | Ssun。。 2026-03-28 | 3/150 |
|
|
|
[考研] 331環(huán)境科學(xué)與工程求調(diào)劑 +3 | 熠然好運(yùn)氣 2026-03-27 | 3/150 |
|
|
|
[考研] 一志愿上海理工能源動力（085800）310分求調(diào)劑 +3 | zhangmingc 2026-03-27 | 4/200 |
|
|
|
[考研] 調(diào)劑求收留 +7 | 果然有我 2026-03-26 | 7/350 |
|